Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASAH1 | Q13510 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.40 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25707541 | 0.97 | ASAH1 (0.40) | ASAH1CNR1HDAC6EPHX2PLA2G2A | |
| SCHEMBL23373405 | 0.95 | ASAH1 (0.43) | ASAH1CNR1HDAC6EPHX2PLA2G2A | |
| SCHEMBL21297524 | 0.93 | ASAH1 (0.41) | ASAH1CNR1HDAC6EPHX2PLA2G2A | |
| SCHEMBL25707518 | 0.88 | ASAH1 (0.41) | ASAH1CNR1HDAC6EPHX2PLA2G2A | |
| SCHEMBL20650683 | 0.86 | CYP2D6 (0.42) | ALDH1A1 | |
| SCHEMBL18349844 | 0.86 | CYP2D6 (0.42) | PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL13575130 | 0.85 | PLA2G2A (0.44) | PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL10940345 | 0.85 | ASAH1 (0.51) | ASAH1CNR1HDAC6EPHX2 | |
| SCHEMBL23373452 | 0.84 | ASAH1 (0.51) | ASAH1CNR1HDAC6EPHX2ALDH1A1 | |
| SCHEMBL889842 | 0.82 | MEN1 (0.38) | ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192597-A1 | Amorphous Solid Succinylated 3-(Fatty Acid Amido)-2-Hydroxy-1-(Protected Hydroxy)-Propane Salts and Methods of Making the Same | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11530179-B2 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same | GERON CORPORATION (US) | 2022-12-20 | — | — | US | disclosed |
| US-20210147344-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) | 2021-05-20 | — | — | US | disclosed |
| WO-2021086753-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | GERON CORPORATION (US) | 2021-05-06 | — | — | WO | disclosed |
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | GERON CORPORATION (US) | 2019-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392418-B2 | Oligonucleotide compositions and methods of making the same | RNGTT, NSUN2, POLN | ASAH1 3560/4885CNR1 4716/4885HDAC6 2409/4885 |
| US-20230192597-A1 | Amorphous Solid Succinylated 3-(Fatty Acid Amido)-2-Hydroxy-1-(Protected Hydroxy)-Propane Salts and Methods of Making the Same | ELOVL1, ELOVL3, FFAR2 | ASAH1 209/4885CNR1 3148/4885HDAC6 877/4885 |
| US-11530179-B2 | Amorphous solid succinylated 3-(fatty acid amido)-2-hydroxy-1 -(protected hydroxy)-propane salts and methods of making the same | ELOVL1, ELOVL3, FFAR2 | ASAH1 209/4885CNR1 3148/4885HDAC6 877/4885 |
| US-20210147344-A1 | AMORPHOUS SOLID SUCCINYLATED 3-(FATTY ACID AMIDO)-2-HYDROXY-1-(PROTECTED HYDROXY)-PROPANE SALTS AND METHODS OF MAKING THE SAME | ELOVL1, ELOVL3, FFAR2 | ASAH1 209/4885CNR1 3148/4885HDAC6 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.